Germany's VFA warns against wholesale fix

12 January 2009

Germany's research-based pharmaceutical industry association, the VFA, has responded to a draft proposal by the Federal Department of Health to  force drugmakers to supply pharmacies at least partly via wholesalers.  The move is seen as an effort to prevent the recent trend towards  direct-to-pharmacy distribution arrangements, which have especially been  developed in the UK (Marketletters passim).

Cornelia Yzer, the VFA's chief executive, responded to the news, saying:  "in principle, the pharmaceutical industry stands for a plurality of  sales routes. Therefore the manufacturer must be able to make the  decision whether he selects direct over wholesale." She criticized  attempts to second-guess the most efficient distribution model by  legislators, adding: "a competitive solution, which leaves it to the  market, which delivery models succeed in the future, would be a better  watchword."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight